Hormone Replacement Therapy (HRT): Benefits, Safety, and Modern Medical Evidence

What Is Hormone Replacement Therapy (HRT)?

Hormone Replacement Therapy (HRT) is a medical treatment designed to restore declining hormone levels in men and women when symptoms and laboratory findings indicate deficiency.

Hormones are biochemical messengers produced by endocrine glands that regulate metabolism, bone density, muscle mass, mood, cognition, cardiovascular function, sexual health, and overall vitality.

With aging, most hormone levels decline gradually—with the exception of cortisol, which may remain stable or even increase under chronic stress conditions. The most clinically relevant age-related declines occur in:

• Estrogens (Estradiol – E2)

• Progesterone

• Testosterone

These changes are often associated with characteristic symptoms and measurable physiologic effects.

Estrogen & Progesterone in Women

Estradiol (E2)

Estradiol is the primary and most biologically active estrogen during reproductive years. Levels decline significantly during perimenopause and menopause, leading to systemic changes.

Common Effects of Estrogen Decline

• Decreased bone mineral density (increased fracture risk)

• Loss of muscle mass

• Skin thinning and decreased elasticity

• Hair thinning

• Vaginal dryness and genitourinary syndrome of menopause (GSM)

• Vasomotor symptoms (hot flashes, night sweats)

• Sleep disturbance

• Mood changes and emotional lability

• Decreased libido

• Joint discomfort

• Cognitive complaints (“brain fog”)

Progesterone decline may contribute to:

• Sleep disturbances

• Anxiety

• Endometrial hyperplasia risk (if estrogen is given unopposed in women with uterus)

Testosterone in Men (And Women)

Testosterone in Men

Testosterone is the principal androgen in men and begins to decline gradually after the late 20s to early 30s at approximately 1–2% per year.

By age 40–45, some men may demonstrate clinically significant reductions, especially in the presence of metabolic syndrome, obesity, diabetes, or chronic illness.

Symptoms of Testosterone Deficiency (Male Hypogonadism)

• Reduced muscle mass and strength

• Increased visceral fat

• Decreased libido and erectile dysfunction

• Fatigue

• Depressed mood

• Reduced motivation

• Impaired concentration and memory

• Decreased bone density

Testosterone in Women

Women also produce testosterone in smaller amounts via ovaries and adrenal glands. Age-related decline may contribute to:

• Reduced libido

• Decreased lean muscle mass

• Reduced energy

• Mood changes

Methods of Hormone Replacement

Hormone therapy can be administered in several forms:

For Women:

• Transdermal patches

• Topical creams or gels

• Oral preparations

• Vaginal estrogen (for GSM)

• Subcutaneous pellet insertion

• Injectable formulations (less common)

For Men:

• Intramuscular (IM) injections

• Subcutaneous injections

• Transdermal gels or creams

• Long-acting implants (pellets)

• Oral testosterone undecanoate (FDA-approved formulation)

Selection depends on:

• Individual symptoms

• Laboratory values

• Risk profile

• Personal preference

• Cost considerations

• Contraindications

In our clinical experience at Age-X Clinics, many men prefer IM testosterone due to dose precision and cost-effectiveness, while many women prefer pellet therapy for convenience and steady hormone delivery. When appropriate, bioidentical estradiol and micronized progesterone may be considered.

Safety & Current Evidence

Testosterone Therapy in Men

Large contemporary studies, including the TRAVERSE Trial (2023), demonstrated that testosterone replacement therapy (TRT) did not significantly increase major adverse cardiovascular events in appropriately selected men with hypogonadism and cardiovascular risk factors.

Current consensus indicates:

• TRT does not appear to increase prostate cancer incidence

• TRT is contraindicated in men with active prostate cancer

• PSA monitoring is required

• Hematocrit must be monitored to prevent polycythemia

References:

• N Engl J Med. 2023; TRAVERSE Trial

• Endocrine Society Clinical Practice Guidelines (2018; updates ongoing)

Estrogen Therapy in Women

The Women’s Health Initiative (WHI) initially raised concerns regarding hormone therapy. However, subsequent re-analyses clarified the concept of the “Timing Hypothesis”:

Women who initiate hormone therapy:

• Under age 60

• Or within 10 years of menopause onset

show favorable safety profiles with:

• No increased cardiovascular risk

• No increased breast cancer risk with estrogen-alone therapy

• Improved bone protection

• Reduced fracture risk

• Possible reduction in all-cause mortality in younger menopausal women

Micronized progesterone appears to carry a lower breast cancer risk profile compared to synthetic progestins.

Professional societies such as:

• The North American Menopause Society (NAMS)

• The Endocrine Society

• The American College of Obstetricians and Gynecologists (ACOG)

support individualized hormone therapy in properly screened patients.

Who Should NOT Receive HRT?

Absolute Contraindications (depending on hormone type):

• Active breast cancer (estrogen therapy)

• Active prostate cancer (testosterone therapy)

• Uncontrolled polycythemia

• Active thromboembolic disease

• Severe uncontrolled cardiovascular disease

• Unexplained vaginal bleeding

The Importance of Individualization

Hormone therapy is not a “one-size-fits-all” solution.

Proper management includes:

• Comprehensive history and physical exam

• Baseline labs (hormone levels, CBC, CMP, lipids, PSA when appropriate)

• Risk stratification

• Shared decision-making

• Ongoing monitoring

When carefully selected and monitored, hormone replacement therapy can significantly improve quality of life, metabolic health, bone density, and overall vitality.

FDA Disclaimer

Hormone replacement therapy products approved by the U.S. Food and Drug Administration (FDA) are indicated for specific medical conditions. Some compounded bioidentical hormone preparations are not FDA-approved, and compounded medications have not been evaluated by the FDA for safety, efficacy, or quality.

Testosterone therapy is approved only for men with confirmed hypogonadism due to medical conditions and should not be used for age-related decline without proper evaluation.

Hormone therapy carries potential risks, including cardiovascular events, thromboembolic disease, cancer risk (depending on type and duration), and other adverse effects. Treatment should only be initiated and monitored under the supervision of a qualified healthcare provider.

Selected References

1. The Endocrine Society Clinical Practice Guidelines – Testosterone Therapy in Men (2018).

2. The North American Menopause Society (NAMS) Position Statement (2022).

3. Women’s Health Initiative (WHI) Follow-Up Studies.

4. TRAVERSE Trial. N Engl J Med. 2023.

5. ACOG Practice Bulletin on Hormone Therapy.